Addenda Capital Inc. Sells 127 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Addenda Capital Inc. lessened its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.7% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 19,188 shares of the medical research company’s stock after selling 127 shares during the period. Addenda Capital Inc.’s holdings in Thermo Fisher Scientific were worth $9,555,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. Bernard Wealth Management Corp. bought a new stake in Thermo Fisher Scientific during the fourth quarter worth about $25,000. Barrett & Company Inc. bought a new stake in Thermo Fisher Scientific during the fourth quarter worth about $28,000. FPC Investment Advisory Inc. bought a new stake in Thermo Fisher Scientific during the fourth quarter worth about $28,000. Pillar Financial Advisors LLC bought a new stake in Thermo Fisher Scientific during the fourth quarter worth about $29,000. Finally, Ameriflex Group Inc. bought a new stake in Thermo Fisher Scientific in the fourth quarter valued at approximately $30,000. Institutional investors own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on TMO shares. Citigroup dropped their price objective on Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. Evercore ISI dropped their price objective on Thermo Fisher Scientific from $585.00 to $500.00 and set an “outperform” rating on the stock in a research note on Thursday, April 24th. Argus dropped their price objective on Thermo Fisher Scientific from $620.00 to $470.00 and set a “buy” rating on the stock in a research note on Tuesday, April 29th. Robert W. Baird dropped their price objective on Thermo Fisher Scientific from $603.00 to $573.00 and set an “outperform” rating on the stock in a research note on Thursday, April 24th. Finally, Raymond James restated an “outperform” rating and issued a $667.00 price objective (up previously from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday, February 3rd. Four equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $607.43.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 3,775 shares of the firm’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $532.52, for a total value of $2,010,263.00. Following the sale, the senior vice president now owns 10,816 shares of the company’s stock, valued at approximately $5,759,736.32. This trade represents a 25.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total value of $5,166,700.00. Following the completion of the sale, the chief executive officer now directly owns 115,174 shares in the company, valued at approximately $59,506,950.58. This represents a 7.99% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 14,075 shares of company stock valued at $7,305,942. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Trading Down 0.3%

Shares of NYSE:TMO opened at $402.41 on Friday. The company has a market capitalization of $151.91 billion, a P/E ratio of 24.34, a P/E/G ratio of 2.99 and a beta of 0.82. Thermo Fisher Scientific Inc. has a 1 year low of $390.50 and a 1 year high of $627.88. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The business’s 50 day simple moving average is $430.85 and its 200 day simple moving average is $499.77.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.10 by $0.05. The business had revenue of $10.36 billion for the quarter, compared to the consensus estimate of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The firm’s quarterly revenue was up .2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $5.11 earnings per share. On average, research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Friday, June 13th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 0.43%. The ex-dividend date of this dividend is Friday, June 13th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.09%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.